Please try another search
For the three months ended 31 March 2022, Genematrix Inc revenues increased 42% to W4.87B. Net loss totaled W3.95B vs. income of W740.4M. Revenues reflect Omniplex HPV segment increase of 33% to W4.36B, HCV genotype segment increase from W750K to W240M, South Korea segment increase of 94% to W1.38B. Net loss reflects Research & Development Expense increase of 30% to W862.5M (expense), Commissions increase of 81% to W217.8M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 4866.52 | 3790.2 | 2813.69 | 2079.58 |
Gross Profit | 2807.38 | 1915.77 | 1167.1 | 969.98 |
Operating Income | 944.68 | -645.22 | -436.9 | -501.8 |
Net Income | -3951.71 | -3835.33 | -174.55 | 2281.81 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 36190.52 | 39532.09 | 41758.21 | 41474.34 |
Total Liabilities | 7829.64 | 7211.2 | 5523.37 | 5071.47 |
Total Equity | 28360.89 | 32320.9 | 36234.84 | 36402.87 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | 1085.32 | 3369.25 | 2294.04 | 1387.39 |
Cash From Investing Activities | 1000 | -780.37 | -769.17 | -742.39 |
Cash From Financing Activities | -12.41 | -123.21 | 17.19 | 12.35 |
Net Change in Cash | 2389.57 | 3266.75 | 2337.97 | 961.75 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review